In development: Guidance, quality standards and advice

Showing 1 to 10 of 29

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	7 May 2026
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance	TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis	Interventional procedures guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]	Technology appraisal guidance	TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	11 February 2026